178
G. Yang and Y. Huang
250. Ali MY, Tariq I, Farhan Sohail M, Amin MU, Ali S, Pinnapireddy SR, Ali A, Schafer J,
Bakowsky U (2019) Selective anti-ErbB3 aptamer modified sorafenib microparticles: In vitro
and in vivo toxicity assessment. Eur J Pharm Biopharm 145 (1873–3441 (Electronic)):42-53
251. Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W, Zhao L, Tang SC, Wu D, Korkaya H,
Maihle NJ, Liu HY (2018) Targeting EGFR/HER2/HER3 with a three-in-one aptamer-siRNA
chimera confers superior activity against HER2(+) breast cancer. Mol Ther Nucleic Acids 10
(2162–2531 Print):317–330
252. Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski
A, Burger JA (2014) The spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes
with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood
123(7):1032–1039
253. Marasca R, Maffei R (2014) NOX-A12: mobilizing CLL away from home. Blood 123(7):952–
953
254. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine
MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ (2006) A
novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and
tumor development. J Exp Med 203(9):2201–2213
255. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S,
Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA (2014) PD1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors.
J Clin Invest 124(5):2246–2259
256. Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariepy J (2015) Targeting
the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for
the treatment of disseminated cancers. Mol Ther Nucleic Acids 4:e237
257. Lai WY, Huang BT, Wang JW, Lin PY, Yang PC (2016) A novel PD-L1-targeting antagonistic
DNA aptamer with antitumor effects. Mol Ther Nucleic Acids 5(12):e397
258. Mann AP, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, Ferrari M, Gorenstein DG, Tanaka T (2010) Identification of thioaptamer ligand against E-selectin: potential
application for inflamed vasculature targeting. PLOS ONE 5(9):e13050
259. Kang SA, Hasan N, Mann AP, Zheng W, Zhao L, Morris L, Zhu W, Zhao YD, Suh KS,
Dooley WC, Volk D, Gorenstein DG, Cristofanilli M, Rui H, Tanaka T (2015) Blocking the
adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. Mol
Ther 23(6):1044–1054
260. Morita Y, Kamal M, Kang SA, Zhang R, Lokesh GL, Thiviyanathan V, Hasan N, Woo S, Zhao
D, Leslie M, Suh S, Razaq W, Rui H, Gorenstein DG, Volk DE, Tanaka T (2016) E-selectin
targeting PEGylated-thioaptamer prevents breast cancer metastases. Mol Ther Nucleic Acids
5(12):e399
261. Mann AP, Bhavane RC, Somasunderam A, Liz Montalvo-Ortiz B, Ghaghada KB, Volk D,
Nieves-Alicea R, Suh KS, Ferrari M, Annapragada A, Gorenstein DG, Tanaka T (2011)
Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget 2(4):298–304
262. Mai J, Huang Y, Mu C, Zhang G, Xu R, Guo X, Xia X, Volk DE, Lokesh GL, Thiviyanathan
V, Gorenstein DG, Liu X, Ferrari M, Shen H (2014) Bone marrow endothelium-targeted
therapeutics for metastatic breast cancer. J Control Release 187 (1873–4995 Electronic):22–29
G. Yang and Y. Huang
250. Ali MY, Tariq I, Farhan Sohail M, Amin MU, Ali S, Pinnapireddy SR, Ali A, Schafer J,
Bakowsky U (2019) Selective anti-ErbB3 aptamer modified sorafenib microparticles: In vitro
and in vivo toxicity assessment. Eur J Pharm Biopharm 145 (1873–3441 (Electronic)):42-53
251. Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W, Zhao L, Tang SC, Wu D, Korkaya H,
Maihle NJ, Liu HY (2018) Targeting EGFR/HER2/HER3 with a three-in-one aptamer-siRNA
chimera confers superior activity against HER2(+) breast cancer. Mol Ther Nucleic Acids 10
(2162–2531 Print):317–330
252. Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski
A, Burger JA (2014) The spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes
with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood
123(7):1032–1039
253. Marasca R, Maffei R (2014) NOX-A12: mobilizing CLL away from home. Blood 123(7):952–
953
254. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine
MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ (2006) A
novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and
tumor development. J Exp Med 203(9):2201–2213
255. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S,
Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA (2014) PD1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors.
J Clin Invest 124(5):2246–2259
256. Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariepy J (2015) Targeting
the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for
the treatment of disseminated cancers. Mol Ther Nucleic Acids 4:e237
257. Lai WY, Huang BT, Wang JW, Lin PY, Yang PC (2016) A novel PD-L1-targeting antagonistic
DNA aptamer with antitumor effects. Mol Ther Nucleic Acids 5(12):e397
258. Mann AP, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, Ferrari M, Gorenstein DG, Tanaka T (2010) Identification of thioaptamer ligand against E-selectin: potential
application for inflamed vasculature targeting. PLOS ONE 5(9):e13050
259. Kang SA, Hasan N, Mann AP, Zheng W, Zhao L, Morris L, Zhu W, Zhao YD, Suh KS,
Dooley WC, Volk D, Gorenstein DG, Cristofanilli M, Rui H, Tanaka T (2015) Blocking the
adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. Mol
Ther 23(6):1044–1054
260. Morita Y, Kamal M, Kang SA, Zhang R, Lokesh GL, Thiviyanathan V, Hasan N, Woo S, Zhao
D, Leslie M, Suh S, Razaq W, Rui H, Gorenstein DG, Volk DE, Tanaka T (2016) E-selectin
targeting PEGylated-thioaptamer prevents breast cancer metastases. Mol Ther Nucleic Acids
5(12):e399
261. Mann AP, Bhavane RC, Somasunderam A, Liz Montalvo-Ortiz B, Ghaghada KB, Volk D,
Nieves-Alicea R, Suh KS, Ferrari M, Annapragada A, Gorenstein DG, Tanaka T (2011)
Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget 2(4):298–304
262. Mai J, Huang Y, Mu C, Zhang G, Xu R, Guo X, Xia X, Volk DE, Lokesh GL, Thiviyanathan
V, Gorenstein DG, Liu X, Ferrari M, Shen H (2014) Bone marrow endothelium-targeted
therapeutics for metastatic breast cancer. J Control Release 187 (1873–4995 Electronic):22–29